Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
Madeline Bross, Melody Hackett, Evanthia Bernitsas
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4312-4312
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment
Rodica Bălașa, Laura Bărcuțean, Oana Mosora, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8370-8370
Open Access | Times Cited: 107
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
Zhuoyi Liu, Qiao Liao, Haicheng Wen, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 6, pp. 102826-102826
Closed Access | Times Cited: 63
Role of fenofibrate in multiple sclerosis
Ahmad Abulaban, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data
Aigli G. Vakrakou, Anastasia Alexaki, Maria-Evgenia Brinia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8077-8077
Open Access | Times Cited: 36
Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Neuropsychopharmacology Reports (2024) Vol. 44, Iss. 3, pp. 639-649
Open Access | Times Cited: 7
New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration
Maria Podbielska, Joan O’Keeffe, Anna Pokryszko−Dragan
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7319-7319
Open Access | Times Cited: 37
Quantitative magnetization transfer imaging in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis
Elizabeth N. York, Michael J. Thrippleton, Rozanna Meijboom, et al.
Brain Communications (2022) Vol. 4, Iss. 2
Open Access | Times Cited: 25
Role of lipoic acid in multiple sclerosis
Hongsheng Xie, Xiufang Yang, Yuan Cao, et al.
CNS Neuroscience & Therapeutics (2021) Vol. 28, Iss. 3, pp. 319-331
Open Access | Times Cited: 28
Huangqi-Guizhi-Wuwu Decoction regulates differentiation of CD4+ T cell and prevents against experimental autoimmune encephalomyelitis progression in mice
Nuo Xu, Xinyan Han, Xiaojuan Zhang, et al.
Phytomedicine (2023), pp. 155239-155239
Closed Access | Times Cited: 12
Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
Ariane Mwema, Giulio G. Muccioli, Anne des Rieux
Journal of Controlled Release (2023) Vol. 364, pp. 435-457
Closed Access | Times Cited: 11
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
An expanded polyglutamine in ATAXIN1 results in a loss-of-function that exacerbates severity of Multiple Sclerosis in an EAE mouse model
Gourango Talukdar, Lisa Duvick, Praseuth Yang, et al.
Research Square (Research Square) (2025)
Closed Access
An expanded polyglutamine in ATAXIN1 results in a loss-of-function that exacerbates severity of Multiple Sclerosis in an EAE mouse model
Gourango Talukdar, Lisa Duvick, Praseuth Yang, et al.
Journal of Neuroinflammation (2025) Vol. 22, Iss. 1
Open Access
Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
Claire Bridel, Cyra E Leurs, Zoë YGJ van Lierop, et al.
Neurology (2021) Vol. 97, Iss. 19
Open Access | Times Cited: 24
Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
Joke Temmerman, Sebastiaan Engelborghs, Maria Bjerke, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study
Andrea I. Ciplea, Anna Kurzeja, Sandra Thiel, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 10, pp. 1641-1650
Open Access | Times Cited: 14
Progressive Loss of Corneal and Retinal Nerve Fibers in Patients With Multiple Sclerosis: A 2-Year Follow-up Study
Gülfidan Bitirgen, Zehra Akpınar, Ali Ulvi Uca, et al.
Translational Vision Science & Technology (2020) Vol. 9, Iss. 13, pp. 37-37
Open Access | Times Cited: 19
In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
Fianne L. P. Sips, Francesco Pappalardo, Giulia Russo, et al.
BMC Medical Informatics and Decision Making (2022) Vol. 22, Iss. S6
Open Access | Times Cited: 12
Anti-inflammatory mechanisms and pharmacological actions of phycocyanobilin in a mouse model of experimental autoimmune encephalomyelitis: A therapeutic promise for multiple sclerosis
Javier Marín‐Prida, Nancy Pavón‐Fuentes, Nielsen Lagumersindez-Denis, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Ultrastructural Characterization of PBMCs and Extracellular Vesicles in Multiple Sclerosis: A Pilot Study
Roberto De Masi, Stefania Orlando, Elisabetta Carata, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6867-6867
Open Access | Times Cited: 2
The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis
Anastasiya Sviridova, Vladimir Rogovskii, В. С. Кудрин, et al.
Journal of Neuroimmunology (2021) Vol. 356, pp. 577608-577608
Closed Access | Times Cited: 15
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
Shannon Kolind, Laura Gaetano, Haz-Edine Assemlal, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 6, pp. 741-747
Open Access | Times Cited: 6
Neuroimaging Technology in Exercise Neurorehabilitation Research in Persons with MS: A Scoping Review
Brian M. Sandroff, Caroline M. Rafizadeh, Robert W. Motl
Sensors (2023) Vol. 23, Iss. 9, pp. 4530-4530
Open Access | Times Cited: 6
Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis
Rina Aharoni, Raya Eilam, Shaul Lerner, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13419-13419
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top